Literature DB >> 16479011

The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors.

Mélanie Franco1, Olivia Furstoss, Valérie Simon, Chrsitine Benistant, Wan Jing Hong, Serge Roche.   

Abstract

The Src family of protein-tyrosine kinases (SFK) play important roles in mitogenesis and morphological changes induced by growth factors. The involved substrates are, however, ill defined. Using an antiphosphotyrosine antibody to screen tyrosine-phosphorylated cDNA expression library, we have identified Tom1L1, an adaptor protein of the Tom1 family and a novel substrate and activator of the SFK. Surprisingly, we found that Tom1L1 does not promote DNA synthesis induced by Src. Furthermore, we report that Tom1L1 negatively regulates SFK mitogenic signaling induced by platelet-derived growth factor (PDGF) through modulation of SFK-receptor association: (i) Tom1L1 inhibits DNA synthesis induced by PDGF; (ii) inhibition is overcome by c-myc expression or p53 inactivation, two regulators of SFK mitogenic function; (iii) Src or Fyn coexpression overrides Tom1L1 mitogenic activity; (iv) overexpression of the adaptor reduces Src association with the receptor; and (v) protein inactivation potentiates receptor complex formation, allowing increased SFK activation and DNA synthesis. However, Tom1L1 affects neither DNA synthesis induced by the constitutively active allele SrcY527F nor SFK-regulated actin assembly induced by PDGF. Finally, overexpressed Tom1 and Tom1L2 also associate with Src and affected mitogenic signaling in agreement with some redundancy among members of the Tom1 family. We concluded that Tom1L1 defines a novel mechanism for regulation of SFK mitogenic signaling induced by growth factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16479011      PMCID: PMC1430241          DOI: 10.1128/MCB.26.5.1932-1947.2006

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

1.  STAM2, a new member of the STAM family, binding to the Janus kinases.

Authors:  K Endo; T Takeshita; H Kasai; Y Sasaki; N Tanaka; H Asao; K Kikuchi; M Yamada; M Chenb; J J O'Shea; K Sugamura
Journal:  FEBS Lett       Date:  2000-07-14       Impact factor: 4.124

2.  Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes.

Authors:  Béatrice Orsetti; Mélanie Nugoli; Nathalie Cervera; Laurence Lasorsa; Paul Chuchana; Lisa Ursule; Catherine Nguyen; Richard Redon; Stanislas du Manoir; Carmen Rodriguez; Charles Theillet
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

Review 3.  Structure and regulation of Src family kinases.

Authors:  Titus J Boggon; Michael J Eck
Journal:  Oncogene       Date:  2004-10-18       Impact factor: 9.867

Review 4.  The interplay between Src family kinases and receptor tyrosine kinases.

Authors:  Paul A Bromann; Hasan Korkaya; Sara A Courtneidge
Journal:  Oncogene       Date:  2004-10-18       Impact factor: 9.867

5.  Catalytic specificity of protein-tyrosine kinases is critical for selective signalling.

Authors:  Z Songyang; K L Carraway; M J Eck; S C Harrison; R A Feldman; M Mohammadi; J Schlessinger; S R Hubbard; D P Smith; C Eng
Journal:  Nature       Date:  1995-02-09       Impact factor: 49.962

6.  DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases.

Authors:  S Roche; M Koegl; M V Barone; M F Roussel; S A Courtneidge
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

7.  Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.

Authors:  Si Qing Zhang; Wentian Yang; Maria I Kontaridis; Trever G Bivona; Gengyun Wen; Toshiyuki Araki; Jincai Luo; Julie A Thompson; Burkhart L Schraven; Mark R Philips; Benjamin G Neel
Journal:  Mol Cell       Date:  2004-02-13       Impact factor: 17.970

8.  The catalytic subunit of phosphatidylinositol 3-kinase is a substrate for the activated platelet-derived growth factor receptor, but not for middle-T antigen-pp60c-src complexes.

Authors:  S Roche; R Dhand; M D Waterfield; S A Courtneidge
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

9.  Rapid and efficient purification of Src homology 2 domain-containing proteins: Fyn, Csk and phosphatidylinositol 3-kinase p85.

Authors:  M Koegl; R M Kypta; M Bergman; K Alitalo; S A Courtneidge
Journal:  Biochem J       Date:  1994-09-15       Impact factor: 3.857

10.  Activation of the pp60c-src kinase by middle T antigen binding or by dephosphorylation.

Authors:  S A Courtneidge
Journal:  EMBO J       Date:  1985-06       Impact factor: 11.598

View more
  19 in total

1.  Penetrance of craniofacial anomalies in mouse models of Smith-Magenis syndrome is modified by genomic sequence surrounding Rai1: not all null alleles are alike.

Authors:  Jiong Yan; Weimin Bi; James R Lupski
Journal:  Am J Hum Genet       Date:  2007-01-18       Impact factor: 11.025

2.  Analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts.

Authors:  Audrey Sirvent; Oana Vigy; Beatrice Orsetti; Serge Urbach; Serge Roche
Journal:  Mol Cell Proteomics       Date:  2012-09-29       Impact factor: 5.911

3.  Temporal Profiling of Astrocyte Precursors Reveals Parallel Roles for Asef during Development and after Injury.

Authors:  Lesley S Chaboub; Jeanne M Manalo; Hyun Kyoung Lee; Stacey M Glasgow; Fengju Chen; Yoshihiro Kawasaki; Tetsu Akiyama; Chay T Kuo; Chad J Creighton; Carrie A Mohila; Benjamin Deneen
Journal:  J Neurosci       Date:  2016-11-23       Impact factor: 6.167

4.  MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells.

Authors:  Kang Kang; Xiao Peng; Xiaoying Zhang; Yuna Wang; Lishu Zhang; Li Gao; Tingting Weng; Honghao Zhang; Ramaswamy Ramchandran; J Usha Raj; Deming Gou; Lin Liu
Journal:  J Biol Chem       Date:  2013-07-12       Impact factor: 5.157

5.  Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.

Authors:  Jonathan R St-Germain; Paul Taylor; Jiefei Tong; Lily L Jin; Ana Nikolic; Ian I Stewart; Robert M Ewing; Moyez Dharsee; Zhihua Li; Suzanne Trudel; Michael F Moran
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

6.  Tom1l2 hypomorphic mice exhibit increased incidence of infections and tumors and abnormal immunologic response.

Authors:  Santhosh Girirajan; Paula M Hauck; Stephen Williams; Christopher N Vlangos; Barbara B Szomju; Sara Solaymani-Kohal; Philip D Mosier; Kimber L White; Kathleen McCoy; Sarah H Elsea
Journal:  Mamm Genome       Date:  2008-03-15       Impact factor: 2.957

7.  TOM1L is involved in a novel signaling pathway important for the IL-2 production in Jurkat T cells stimulated by CD3/CD28 co-ligation.

Authors:  Ahmed Elmarghani; Hanan Abuabaid; Peter Kjellen
Journal:  Mediators Inflamm       Date:  2010-02-21       Impact factor: 4.711

8.  Vesicular trafficking regulators are new players in breast cancer progression: Role of TOM1L1 in ERBB2-dependent invasion.

Authors:  Clément Chevalier; Serge Roche; Christine Bénistant
Journal:  Mol Cell Oncol       Date:  2016-04-28

9.  The Tom1L1-clathrin heavy chain complex regulates membrane partitioning of the tyrosine kinase Src required for mitogenic and transforming activities.

Authors:  Guillaume Collin; Mélanie Franco; Valérie Simon; Christine Bénistant; Serge Roche
Journal:  Mol Cell Biol       Date:  2007-09-04       Impact factor: 4.272

10.  Participation of Tom1L1 in EGF-stimulated endocytosis of EGF receptor.

Authors:  Ning Sheng Liu; Li Shen Loo; Eva Loh; Li-Fong Seet; Wanjin Hong
Journal:  EMBO J       Date:  2009-10-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.